Viral hepatitis vaccines.
Purified from the plasma of hepatitis B carriers, hepatitis B surface antigen particles have been used in a vaccine to prevent hepatitis B. This plasma-derived vaccine is immunogenic, protective, and has an excellent safety record. Indications and strategies for preexposure and postexposure prophylaxis are reviewed. In addition, novel approaches to hepatitis B vaccine development are being pursued and will provide the basis for the next generation of vaccines. Early progress has also been made toward a hepatitis A vaccine, but clinical availability is not imminent.
D000328:Adult; D002648:Child; D003362:Cost-Benefit Analysis; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000517:prevention & control*; D006801:Humans; D007116:Immunization, Passive; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007231:Infant, Newborn; D014611:Vaccination / Q000191:economics; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology
D006514:Hepatitis B Surface Antigens; D014765:Viral Vaccines